S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
NASDAQ:MDGL

Madrigal Pharmaceuticals - MDGL Stock Forecast, Price & News

$73.34
+3.13 (+4.46%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$70.21
$74.27
50-Day Range
$60.57
$84.65
52-Week Range
$52.33
$105.93
Volume
183,843 shs
Average Volume
175,394 shs
Market Capitalization
$1.25 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$161.00

Madrigal Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
119.5% Upside
$161.00 Price Target
Short Interest
Bearish
12.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
1.39mentions of Madrigal Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($15.19) to ($12.28) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

315th out of 1,135 stocks

Pharmaceutical Preparations Industry

160th out of 557 stocks

MDGL stock logo

About Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals Price Performance

Shares of NASDAQ:MDGL traded up $3.13 during midday trading on Friday, reaching $73.34. The company's stock had a trading volume of 183,843 shares, compared to its average volume of 175,394. Madrigal Pharmaceuticals has a fifty-two week low of $52.33 and a fifty-two week high of $105.93. The company has a market capitalization of $1.25 billion, a P/E ratio of -4.87 and a beta of 1.05. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.55 and a quick ratio of 2.55. The business's fifty day simple moving average is $71.22 and its 200-day simple moving average is $77.41.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on MDGL shares. Canaccord Genuity Group upped their price target on shares of Madrigal Pharmaceuticals from $133.00 to $151.00 and gave the company a "buy" rating in a report on Thursday, May 12th. B. Riley downgraded Madrigal Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $131.00 to $75.00 in a report on Friday, July 8th. Finally, Oppenheimer lowered their price target on Madrigal Pharmaceuticals from $180.00 to $170.00 in a report on Tuesday, May 10th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $161.00.

Receive MDGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MDGL Stock News Headlines

Madrigal: NASH Data In Q4 Is The Key
Madrigal Pharmaceuticals Q4 net loss widens Y/Y
See More Headlines
Receive MDGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MDGL Company Calendar

Last Earnings
11/04/2021
Today
8/13/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MDGL
CUSIP
87162T20
Employees
71
Year Founded
2011

Price Target and Rating

Average Stock Price Forecast
$161.00
High Stock Price Forecast
$220.00
Low Stock Price Forecast
$75.00
Forecasted Upside/Downside
+119.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-241,850,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.88 per share

Miscellaneous

Free Float
12,022,000
Market Cap
$1.25 billion
Optionable
Optionable
Beta
1.05

Social Links


Key Executives

  • Dr. Paul A. Friedman M.D. (Age 79)
    Chairman & CEO
    Comp: $1.05M
  • Dr. Rebecca A. Taub M.D. (Age 70)
    Founder, Chief Medical Officer, Pres of R&D and Director
    Comp: $854.75k
  • Mr. Alex G. Howarth (Age 53)
    Sr. VP & CFO
    Comp: $605.3k
  • Mr. Brian J. Lynch J.D. (Age 60)
    Sr. VP & Gen. Counsel
    Comp: $699.28k
  • Mr. Remy Sukhija (Age 50)
    Sr. VP & Chief Commercial Officer
    Comp: $720.07k
  • Dr. Kianoush Motesharei Ph.d. (Age 52)
    Sr. VP of Bus. & Corp. Devel.
  • Mr. Edward Chiang
    Sr. VP of Clinical & Technical Operations
  • Mr. Thomas W. Hare
    Sr. VP of Clinical Management
  • Dr. Robert E. Waltermire Ph.D. (Age 58)
    Chief Pharmaceutical Devel. Officer
  • Dr. Stephen Dodge M.B.A.
    Pharm.D., Sr. VP of Global Medical Affairs













MDGL Stock - Frequently Asked Questions

Should I buy or sell Madrigal Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDGL shares.
View MDGL analyst ratings
or view top-rated stocks.

What is Madrigal Pharmaceuticals' stock price forecast for 2022?

5 brokers have issued 12-month price objectives for Madrigal Pharmaceuticals' shares. Their MDGL share price forecasts range from $75.00 to $220.00. On average, they expect the company's stock price to reach $161.00 in the next year. This suggests a possible upside of 119.5% from the stock's current price.
View analysts price targets for MDGL
or view top-rated stocks among Wall Street analysts.

How have MDGL shares performed in 2022?

Madrigal Pharmaceuticals' stock was trading at $84.74 at the beginning of the year. Since then, MDGL shares have decreased by 13.5% and is now trading at $73.34.
View the best growth stocks for 2022 here
.

When is Madrigal Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our MDGL earnings forecast
.

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) issued its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($3.79) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.87) by $0.08.

What other stocks do shareholders of Madrigal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Advaxis (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild).

What is Madrigal Pharmaceuticals' stock symbol?

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

Who are Madrigal Pharmaceuticals' major shareholders?

Madrigal Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Artisan Partners Limited Partnership (1.24%), Jennison Associates LLC (1.07%), FMR LLC (0.96%), Northern Trust Corp (0.67%), Affinity Asset Advisors LLC (0.58%) and Hennion & Walsh Asset Management Inc. (0.35%). Insiders that own company stock include Bay City Capital Llc and Fred B Craves.
View institutional ownership trends
.

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Madrigal Pharmaceuticals' stock price today?

One share of MDGL stock can currently be purchased for approximately $73.34.

How much money does Madrigal Pharmaceuticals make?

Madrigal Pharmaceuticals (NASDAQ:MDGL) has a market capitalization of $1.25 billion. The biopharmaceutical company earns $-241,850,000.00 in net income (profit) each year or ($15.07) on an earnings per share basis.

When was Madrigal Pharmaceuticals founded?

Madrigal Pharmaceuticals was founded in 2011.

How can I contact Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The official website for the company is www.madrigalpharma.com. The biopharmaceutical company can be reached via phone at (484) 380-9263, via email at ir@madrigalpharma.com, or via fax at 781-274-8228.

This page (NASDAQ:MDGL) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.